On June 13, 2026, Sanofi announced that the U.S. regulatory authorities approved Tzield as the first disease-modifying therapy for patients recently diagnosed with stage 3 type 1 diabetes. Sanofi is a pharmaceutical company that develops and manufactures medicines and vaccines.
